

High-Level Pan-Azole-Resistant Aspergillosis

Jakko van Ingen, Henrich A. L. van der Lee, Antonius J. M. M. Rijs, Eveline Snelders, Willem J. G. Melchers, Paul E. Verweij

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands

High-level pan-azole-resistant *Aspergillus fumigatus* was recovered from four patients with chronic lung disease. In one patient, the development of progressive resistance followed long-term azole therapy and switching between antifungal azoles. The high-level pan-azole-resistant phenotypes were not associated with a specific *cyp51A* gene mutation. New strategies that avoid the development of progressive azole resistance are needed.

Azole resistance in *Aspergillus fumigatus* is an emerging problem which is associated with treatment failure in patients with aspergillus diseases (1). Resistance is commonly due to mutations in the *cyp51A* gene (1) that typically lead to high-level resistance (MIC, ≥ 8 mg/liter) against one azole and low-level resistance (MICs close to the resistance breakpoint) against others (2, 3).

We identified four *A. fumigatus* isolates with MIC of ≥ 8 mg/liter for all mold-active azoles, measured using EUCAST methodology (4). We labeled this unique phenotype high-level pan-azole resistance. We analyzed the *cyp51A* gene sequence of the isolates, using previously published algorithms (5), and retrieved clinical data for these four patients (Table 1).

The first patient was a 22-year-old male with cystic fibrosis. After being diagnosed with allergic bronchopulmonary aspergillosis (ABPA), he commenced itraconazole and steroid maintenance therapy. Fungal sputum cultures after 8 months of itraconazole therapy revealed an *A. fumigatus* isolate with the high-level pan-azole-resistant phenotype. The patient continued itraconazole maintenance therapy, and the high-level pan-azole-resistant isolate was not recovered from repeat cultures.

The second patient was a 71-year-old male with a medical history of asthma, bronchiectasis, and intermittent culture positivity with itraconazole- and voriconazole-susceptible *A. fumigatus*. The patient did not meet diagnostic criteria for ABPA and was never treated with azoles. The high-level pan-azole-resistant *A. fumigatus* isolate was isolated once from a sputum sample; follow-up sputum cultures yielded azole-susceptible *A. fumigatus*.

The third patient was a 47-year-old female with severe pulmonary sarcoidosis, complicated by a pneumothorax with subsequent pleural empyema. From this empyema, an azole-susceptible *A. fumigatus* isolate was cultured (itraconazole and voriconazole MICs, 0.5 mg/liter; posaconazole MIC, 0.063 mg/liter). Treatment with itraconazole was started, later changed to voriconazole, and ultimately changed to posaconazole as a chronic suppressive therapy. After 18 months of azole therapy, the patient's disease progressed, and a sputum sample was ordered for fungal culture. This sample grew the high-level pan-azole-resistant isolate and induced a switch to liposomal amphotericin B therapy. Despite treatment, the patient's condition deteriorated, and she died of respiratory failure.

The fourth patient was a 39-year-old male diagnosed with chronic granulomatous disease and ABPA. The patient had been treated for multiple episodes of invasive pulmonary aspergillosis, and he received secondary prophylaxis with itraconazole. He then presented with arthritis of the sternoclavicular joint, and itraconazole-resistant *A. fumigatus* was cultured from biopsy specimens.

Treatment with voriconazole was initiated, but visual disturbances forced a switch to liposomal amphotericin B and anidulafungin. The patient responded and was discharged on posaconazole maintenance therapy. After 11 months, the patient presented with increasing dyspnea, dry cough, and fever. A chest computed tomography (CT) scan revealed a cavity and bronchiolitis in the right lower lobe. Bronchoalveolar lavage cultures were positive for *A. fumigatus*, which exhibited the high-level pan-azole-resistant phenotype and an M220R mutation in the *cyp51A* gene, absent in the patient's previous isolates. Micafungin was added to posaconazole, based on susceptibility test results (Table 1). After 1 and 7 days of treatment, follow-up cultures remained positive for the high-level pan-azole-resistant strain. After 10 days of therapy, the patient died of pulmonary hemorrhage. Microsatellite typing (4) showed that the isolates from this patient were isogenic.

The isolates cultured from these four patients reveal a new and highly worrisome phenotype characterized by high-level resistance to all mold-active azoles, including the new azole isavuconazole. Isavuconazole was shown to exhibit cross-resistance to voriconazole (6). All patients had chronic lung diseases, and a chronic aspergillus disease was diagnosed in three patients. In patients 1 and 2, there were no clinical factors that might explain the single recovery of the high-level pan-azole-resistant *A. fumigatus* isolates. The high-level pan-azole-resistant isolates might have been acquired as such from the environment (7).

In patient 3, a persisting aspergillus infection was treated with various antifungal azoles. Although the initial isolate was azole susceptible, the high-level pan-azole-resistant isolate with an environmental resistance mechanism (TR₄₆/Y121F/T289A) was cultured during therapy. The high-level pan-azole-resistant phenotype may have developed during azole therapy or may have been acquired as such from the environment. Clear evidence for the development of progressive resistance was present in patient 4. As

Received 23 February 2015 Returned for modification 23 March 2015

Accepted 16 April 2015

Accepted manuscript posted online 22 April 2015

Citation van Ingen J, van der Lee HAL, Rijs AJMM, Snelders E, Melchers WJG, Verweij PE. 2015. High-level pan-azole-resistant aspergillosis. *J Clin Microbiol* 53:2343–2345. doi:10.1128/JCM.00502-15.

Editor: D. W. Warnock

Address correspondence to Paul E. Verweij, paul.verweij@radboudumc.nl.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/JCM.00502-15

TABLE 1 Patient characteristics, azole *in vitro* activities, and *cyp51A* resistance mechanisms in four high-level azole-resistant *A. fumigatus* isolates

Case	Sex ^a /age (yr)	Underlying condition	Aspergillus disease	Prior azole exposure	Origin of isolate	MIC (mg/liter) of ^b :						<i>cyp51A</i> mutation(s)
						AmB	AFG	ITC	VRC	POS	ISA	
1	M/22	Cystic fibrosis	ABPA ^c	ITC	Sputum	1	0.063	>16	16	>16	>16	TR ₃₄ /L98H
2	M/71	Bronchiectasis	None	None	Sputum	1	0.063	>16	>16	>16	>16	None detected
3	F/47	Sarcoidosis	Empyema	ITC, VRC, POS	Sputum	0.5	0.016	>16	>16	>16	>16	TR ₄₆ /Y121F/T298A, M172I, G448S
4	M/39	Chronic granulomatous disease	Chronic invasive aspergillosis	ITC, VRC, POS	BAL ^d specimen	0.5	0.063	>16	8	>16	>16	M220R

^a M, male; F, female.

^b All MICs were determined using EUCAST methodology (2, 4). AmB, amphotericin B; AFG, amphotericin B; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; ISA, isavuconazole.

^c ABPA, allergic bronchopulmonary aspergillosis.

^d BAL, bronchoalveolar lavage.

treatment was switched between the azole compounds, *A. fumigatus* progressively developed resistance to each azole that was used for treatment. Possibly, the cavitory lesions or other difficult-to-reach sites with high fungal burdens facilitated the development of resistance (8).

We were unable to detect genetic changes in the *cyp51A* gene that paralleled the development of the high-level pan-azole-resistant phenotype (Table 1). We did not find known azole resistance mechanisms in the isolate of patient 2, indicating that non-*cyp51A*-mediated resistance mechanisms may have emerged in these isolates. Two isolates (of patients 1 and 3) harbored *cyp51A* mutations that have been associated with environmental azole exposure, TR₃₄/L98H and TR₄₆/Y121F/T289A (1, 4). In the Netherlands, typical MICs of TR₃₄/L98H isolates are >16 mg/liter for itraconazole, 4 to 8 mg/liter for voriconazole, and 1 mg/liter for posaconazole, and those of TR₄₆/Y121F/T298A isolates are >16 mg/liter for voriconazole, variable for itraconazole (1 to >16 mg/liter), and 0.5 to 1 mg/liter for posaconazole (2). The high-level pan-azole-resistant phenotype, particularly the high posaconazole MIC, suggests that these isolates have accumulated additional non-*cyp51A* resistance mechanisms. These could include the recently described overexpression of *cyp51A*, *cyp51B*, and the *cdr1B* efflux pump; for these three mechanisms, MICs of ≥8 mg/liter for itraconazole, 1 to 8 mg/liter for voriconazole, and 0.125 to 2 mg/liter for posaconazole have been measured (9–11). Based on these reported phenotypes, particularly the low-level posaconazole resistance, these mechanisms are unlikely responsible for the high-level pan-azole-resistant phenotype observed in these four patients' isolates.

The M220R mutation (in patient 4) has not been previously reported, but M220K and M220T have been reported to lead to itraconazole MICs of >8 mg/liter but variable MICs for voriconazole (1 to 4 mg/liter) and posaconazole (0.5 to >8 mg/liter), so may equal the phenotype seen in patient 4 (12).

High-level pan-azole resistance has consequences for patient management. Dose escalation of voriconazole, (intravenous) posaconazole, and azole-echinocandin combination therapy may be effective against low-level azole-resistant *A. fumigatus* (3, 13). In a high-level pan-azole-resistant infection, dose escalation will be inadequate and the efficacy of combination therapy, at best, uncertain. The activity of amphotericin B and the echinocandins *in vitro* remained unaffected. Liposomal amphotericin B has shown good efficacy in a nonneutropenic murine model of acute azole-resistant invasive aspergillosis (14).

Direct detection of resistance mutations in clinical samples is increasingly studied (15, 16). These samples indicated a wild-type *cyp51A* gene or the M220R, TR₃₄/L98H, or TR₄₆/Y121F/T289A resistance mechanism, none of which corresponds to the high-level pan-azole resistance phenotype observed in these four patients.

We report the emergence of high-level pan-azole-resistant *A. fumigatus* isolates. This phenotype might originate from the environment but also may develop through switching between azole compounds in patients with chronic aspergillosis. There is a clear need to develop strategies in patients at risk for chronic aspergillosis that avoids high-level resistance development.

ACKNOWLEDGMENTS

We thank Roland W. Brimicombe, Christian F. Melissant, and Ed A. van de Graaf for their assistance in obtaining the clinical data of these patients.

REFERENCES

1. Vermeulen E, Lagrou K, Verweij PE. 2013. Azole resistance in *Aspergillus fumigatus*: a growing public health concern. *Curr Opin Infect Dis* 26:493–500. <http://dx.doi.org/10.1097/QCO.0000000000000005>.
2. van Ingen J, van der Lee HA, Rijs A, Leenstra T, Melchers WJ, Verweij PE. 2015. Azole, polyene, and echinocandin MIC distributions for wild type, TR₃₄/L98H, and TR₄₆/Y121F/T289A *Aspergillus fumigatus* isolates in the Netherlands. *J Antimicrob Chemother* 70:178–181. <http://dx.doi.org/10.1093/jac/dku364>.
3. Seyedmousavi S, Mouton JW, Melchers WJ, Brüggemann RJ, Verweij PE. 2014. The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. *Drug Resist Updat* 17:37–50. <http://dx.doi.org/10.1016/j.drup.2014.06.001>.
4. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW. 2013. Breakpoints for antifungal agents: an update from EUCAST focusing on echinocandins against *Candida* spp. and triazoles against *Aspergillus* spp. *Drug Resist Updat* 16:81–95. <http://dx.doi.org/10.1016/j.drup.2014.01.001>.
5. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp YJ, Haas PJ, Rijnders BJ, Kuijper EJ, van Tiel FH, Varga J, Karawajczyk A, Zoll J, Melchers WJ, Verweij PE. 2013. Aspergillosis due to voriconazole highly resistant *Aspergillus fumigatus* and recovery of genetically related resistant isolates from domiciles. *Clin Infect Dis* 57:513–520. <http://dx.doi.org/10.1093/cid/cit320>.
6. Gregson L, Goodwin J, Johnson A, McEntee L, Moore CB, Richardson M, Hope WW, Howard SJ. 2013. *In vitro* susceptibility of *Aspergillus fumigatus* to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. *Antimicrob Agents Chemother* 57:5778–5780. <http://dx.doi.org/10.1128/AAC.01141-13>.
7. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. 2009. Azole resistance in *Aspergillus fumigatus*: a side effect of environmental fungicide use? *Lancet Infect Dis* 9:789–795. [http://dx.doi.org/10.1016/S1473-3099\(09\)70265-8](http://dx.doi.org/10.1016/S1473-3099(09)70265-8).
8. Camps SM, van der Linden JW, Li Y, Kuijper EJ, van Dissel JT, Verweij PE, Melchers WJ. 2012. Rapid induction of multiple resistance mechanisms in *Aspergillus fumigatus* during azole therapy: a case study and review of the literature. *Antimicrob Agents Chemother* 56:10–16. <http://dx.doi.org/10.1128/AAC.05088-11>.
9. Albarrag AM, Anderson MJ, Howard SJ, Robson GD, Warn PA, Sanglard D, Denning DW. 2011. Interrogation of related clinical pan-azole-resistant *Aspergillus fumigatus* strains: G138C, Y431C, and G434C single nucleotide polymorphisms in *cyp51A*, upregulation of I, and integration and activation of transposon Atf1 in the *cyp51A* promoter. *Antimicrob Agents Chemother* 55:5113–5121. <http://dx.doi.org/10.1128/AAC.00517-11>.
10. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P. 2013. The cdr1B efflux transporter is associated with non-*cyp51a*-mediated itraconazole resistance in *Aspergillus fumigatus*. *J Antimicrob Chemother* 68:1486–1496. <http://dx.doi.org/10.1093/jac/dkt075>.
11. Buied A, Moore CB, Denning DW, Bowyer P. 2013. High-level expression of *cyp51B* in azole-resistant clinical *Aspergillus fumigatus* isolates. *J Antimicrob Chemother* 68:512–514. <http://dx.doi.org/10.1093/jac/dks451>.
12. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, Laverdiere M, Arendrup MC, Perlin DS, Denning DW. 2009. Frequency and evolution of azole resistance in *Aspergillus fumigatus* associated with treatment failure. *Emerg Infect Dis* 15:1068–1076. <http://dx.doi.org/10.3201/eid1507.090043>.
13. Lepak AJ, Marchillo K, VanHecker J, Andes DR. 2013. Impact of *in vivo* triazole and echinocandin combination therapy for invasive pulmonary aspergillosis: enhanced efficacy against Cyp51 mutant isolates. *Antimicrob Agents Chemother* 57:5438–5447. <http://dx.doi.org/10.1128/AAC.00833-13>.
14. Seyedmousavi S, Melchers WJ, Mouton JW, Verweij PE. 2013. Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant *Aspergillus fumigatus* isolates in a murine model of disseminated aspergillosis. *Antimicrob Agents Chemother* 57:1866–1871. <http://dx.doi.org/10.1128/AAC.02226-12>.
15. Denning DW, Park S, Lass-Flörl C, Fraczek MG, Kirwan M, Gore R, Smith J, Buied A, Moore CB, Bowyer P, Perlin DS. 2011. High-frequency triazole resistance found in nonculturable *Aspergillus fumigatus* from lungs of patients with chronic fungal disease. *Clin Infect Dis* 52:1123–1129. <http://dx.doi.org/10.1093/cid/cir179>.
16. Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, Hofmann WK, Buchheidt D. 2012. Development of novel PCR assays to detect azole resistance-mediating mutations of the *Aspergillus fumigatus cyp51A* gene in primary clinical samples from neutropenic patients. *Antimicrob Agents Chemother* 56:3905–3910. <http://dx.doi.org/10.1128/AAC.05902-11>.